{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:00:07Z","timestamp":1790996407481,"version":"4.1.0"},"reference-count":108,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009381","name":"International Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009381","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.drudis.2019.05.003","type":"journal-article","created":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T23:17:42Z","timestamp":1557962262000},"page":"1769-1783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["The current status of pharmacotherapy for the treatment of Parkinson\u2019s disease: transition from single-target to multitarget therapy"],"prefix":"10.1016","volume":"24","author":[{"given":"Siew L.","family":"Cheong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2800-5287","authenticated-orcid":false,"given":"Stephanie","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Spalluto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Norbert","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Pastorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2019.05.003_bib0005","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S1471-1931(00)00028-8","article-title":"Pathophysiology of the basal ganglia in Parkinson\u2019s disease","volume":"23","author":"Obeso","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.drudis.2019.05.003_bib0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0193-953X(03)00106-0","article-title":"Cognitive and neurological impairment in mood disorders","volume":"27","author":"Marvel","year":"2004","journal-title":"Psychiatr. Clin. North. Am."},{"key":"10.1016\/j.drudis.2019.05.003_bib0015","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12264-010-0302-z","article-title":"Treatment strategies for Parkinson\u2019s disease","volume":"26","author":"Yuan","year":"2010","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.drudis.2019.05.003_bib0020","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/npp.2011.212","article-title":"Parkinson\u2019s disease therapeutics: new developments and challenges since the introduction of levodopa","volume":"37","author":"Smith","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2019.05.003_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nurt.2008.11.001","article-title":"Multifunctional drugs as neurotherapeutics","volume":"6","author":"Van der Schyf","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.drudis.2019.05.003_bib0030","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2174\/138161209787315594","article-title":"Designing multiple ligands \u2014 medicinal chemistry strategies and challenges","volume":"15","author":"Morphy","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.drudis.2019.05.003_bib0035","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/2532764","article-title":"Anti-Parkinson drug biperiden inhibits enzyme acetylcholinesterase","volume":"2017","author":"Kostelnik","year":"2017","journal-title":"BioMed. Res. Int."},{"key":"10.1016\/j.drudis.2019.05.003_bib0040","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1124\/mol.54.6.1046","article-title":"Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells","volume":"54","author":"Kitamura","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drudis.2019.05.003_bib0045","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3390\/ijms17060904","article-title":"Neuroprotective and therapeutic strategies against Parkinson\u2019s disease: recent perspectives","volume":"17","author":"Sarkar","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drudis.2019.05.003_bib0050","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1006\/exnr.2000.7350","article-title":"Combined use of the adenosine A(2A) antagonist KW-6002 with l-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys","volume":"162","author":"Kanda","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.drudis.2019.05.003_bib0055","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/mds.23714","article-title":"Milestones in Parkinson\u2019s disease therapeutics","volume":"26","author":"Rascol","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.drudis.2019.05.003_bib0060","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature08506","article-title":"Predicting new molecular targets for known drugs","volume":"462","author":"Keiser","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2019.05.003_bib0065","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.05.003_bib0070","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/014107680609900515","article-title":"Surgical insights into Parkinson\u2019s disease","volume":"99","author":"Pereira","year":"2006","journal-title":"J. R. Soc. Med."},{"key":"10.1016\/j.drudis.2019.05.003_bib0075","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson\u2019s disease: mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2019.05.003_bib0080","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.drudis.2019.05.003_bib0085","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00702-002-0808-2","article-title":"Idiopathic Parkinson\u2019s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen","volume":"110","author":"Braak","year":"2003","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.drudis.2019.05.003_bib0090","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/mds.25032","article-title":"Pathogenesis of Parkinson\u2019s disease","volume":"28","author":"Hirsch","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.drudis.2019.05.003_bib0095","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cell.2011.02.010","article-title":"PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson\u2019s disease","volume":"144","author":"Shin","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2019.05.003_bib0100","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.tibs.2015.02.003","article-title":"Mitochondrial dysfunction and mitophagy in Parkinson\u2019s: from familial to sporadic disease","volume":"40","author":"Ryan","year":"2015","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.drudis.2019.05.003_bib0105","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1111\/febs.14587","article-title":"Crucial role of protein oligomerization in the pathogenesis of Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"285","author":"Choi","year":"2018","journal-title":"FEBS J."},{"key":"10.1016\/j.drudis.2019.05.003_bib0110","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.brainres.2018.06.010","article-title":"LRRK2 and mitochondria: recent advances and current views","volume":"1702","author":"Singh","year":"2019","journal-title":"Brain Res."},{"key":"10.1016\/j.drudis.2019.05.003_bib0115","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nature09536","article-title":"Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1","volume":"468","author":"Guzman","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2019.05.003_bib0120","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1083\/jcb.200908164","article-title":"Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond","volume":"187","author":"Ilieva","year":"2009","journal-title":"J. Cell. Biol."},{"key":"10.1016\/j.drudis.2019.05.003_bib0125","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2019.05.003_bib0130","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/jnc.13570","article-title":"The contribution of alpha synuclein to neuronal survival and function implications for Parkinson\u2019s disease","volume":"3","author":"Benskey","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.drudis.2019.05.003_bib0135","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pneurobio.2017.04.006","article-title":"Old and new challenges in Parkinson\u2019s disease therapeutics","volume":"156","author":"Pires","year":"2017","journal-title":"Prog. Neurobio."},{"key":"10.1016\/j.drudis.2019.05.003_bib0140","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1242\/jcs.180737","article-title":"Ca2+ is a key factor in \u03b1-synuclein-induced neurotoxicity","volume":"129","author":"Angelova","year":"2016","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.drudis.2019.05.003_bib0145","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fnana.2015.00091","article-title":"Oxidative stress and Parkinson\u2019s disease","volume":"9","author":"Blesa","year":"2015","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.drudis.2019.05.003_bib0150","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.freeradbiomed.2012.05.040","article-title":"Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders","volume":"53","author":"Wilhelmus","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.drudis.2019.05.003_bib0155","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neuroscience.2012.02.001","article-title":"Parkinson\u2019s disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity","volume":"208","author":"Gillardon","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.drudis.2019.05.003_bib0160","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrn2038","article-title":"Microglia-mediated neurotoxicity: uncovering the molecular mechanisms","volume":"8","author":"Block","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.drudis.2019.05.003_bib0165","first-page":"182","article-title":"Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease","volume":"119","author":"Brochard","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2019.05.003_bib0170","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40035-017-0099-z","article-title":"Current understanding of the molecular mechanisms in Parkinson\u2019s disease: targets for potential treatments","volume":"6","author":"Maiti","year":"2017","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.drudis.2019.05.003_bib0175","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: a review","volume":"311","author":"Connoly","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2019.05.003_bib0180","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2019.05.003_bib0185","first-page":"307","article-title":"The human experience with intravenous Levodopa","volume":"6","author":"Siddiqui","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drudis.2019.05.003_bib0190","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/bjaed\/mkw050","article-title":"Parkinson\u2019s disease","volume":"17","author":"Chambers","year":"2016","journal-title":"BJA Educ."},{"key":"10.1016\/j.drudis.2019.05.003_bib0195","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of l-DOPA-induced dyskinesia in Parkinson\u2019s disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.drudis.2019.05.003_bib0200","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/mds.27216","article-title":"Levodopa: a new look at an old friend","volume":"33","author":"Olanow","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.drudis.2019.05.003_bib0205","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.50.6_Suppl_6.S2","article-title":"History of levodopa and dopamine agonists in Parkinson\u2019s disease treatment","volume":"50","author":"Tolosa","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2019.05.003_bib0210","first-page":"241","article-title":"Available and emerging treatments for Parkinson\u2019s disease: a review","volume":"5","author":"Hickey","year":"2011","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.drudis.2019.05.003_bib0215","first-page":"403039","article-title":"Dopamine receptors and Parkinson\u2019s disease","volume":"2011","author":"Hishara","year":"2011","journal-title":"Int. J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.05.003_bib0220","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/jpet.102.039867","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes","volume":"303","author":"Millan","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2019.05.003_bib0225","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1124\/jpet.102.039875","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D2-like receptor and \u03b11\/\u03b12-adrenoceptor","volume":"303","author":"Newman-Tancredi","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2019.05.003_bib0230","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/jpet.102.039883","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT1 and 5-HT2, receptor subtypes","volume":"303","author":"Newman-Tancredi","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2019.05.003_bib0235","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00210-008-0341-4","article-title":"The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson\u2019s disease","volume":"379","author":"Scheller","year":"2009","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.drudis.2019.05.003_sbref0240a","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2710.2008.01008.x","article-title":"Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa)","volume":"34","author":"Zhang","year":"2009","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.drudis.2019.05.003_sbref0240b","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1124\/pr.57.2.5","article-title":"International Union of Pharmacology. XLVI. G-protein-coupled receptor list","volume":"57","author":"Steven","year":"2005","journal-title":"Pharm. Rev."},{"key":"10.1016\/j.drudis.2019.05.003_bib0245","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1254\/jjp.77.227","article-title":"Effects of talipexole on contraversive rotation and functional impairment in MPTP-induced chronic hemiparkinsonian monkeys","volume":"77","author":"Domino","year":"1998","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.drudis.2019.05.003_bib0250","doi-asserted-by":"crossref","first-page":"260","DOI":"10.12688\/f1000research.10100.1","article-title":"Recent advances in treating Parkinson\u2019s disease","volume":"6","author":"Oertel","year":"2017","journal-title":"F1000 Res."},{"key":"10.1016\/j.drudis.2019.05.003_bib0255","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/cmdc.201100545","article-title":"Investigation of D2 receptor\u2013agonist interactions using a combination of pharmacophore and receptor homology modeling","volume":"7","author":"Malo","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drudis.2019.05.003_bib0260","article-title":"Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson\u2019s disease","author":"Finberg","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.drudis.2019.05.003_bib0265","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3389\/fphar.2016.00340","article-title":"Inhibitors of MAO-A and MAO-B in psychiatry and neurology","volume":"7","author":"Finberg","year":"2016","journal-title":"Front. Pharm."},{"key":"10.1016\/j.drudis.2019.05.003_bib0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5607\/en.2011.20.1.1","article-title":"MAO-inhibitors in Parkinson\u2019s disease","volume":"20","author":"Riederer","year":"2011","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.drudis.2019.05.003_bib0275","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.drudis.2018.01.033","article-title":"Safinamide: a new hope for Parkinson\u2019s disease?","volume":"23","author":"Teixeira","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2019.05.003_bib0280","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1586\/14737175.2016.1150783","article-title":"The safety and efficacy of safinamide mesylate for the treatment of Parkinson\u2019s disease","volume":"16","author":"Perez-Lloret","year":"2016","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.drudis.2019.05.003_bib0285","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s40265-016-0623-y","article-title":"Opicapone: a review in Parkinson\u2019s disease","volume":"76","author":"Scott","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2019.05.003_bib0290","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/mds.26102","article-title":"The medical treatment of Parkinson disease from James Parkinson to George Cotzias","volume":"30","author":"Fahn","year":"2015","journal-title":"Mov. Dis."},{"key":"10.1016\/j.drudis.2019.05.003_bib0295","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0022-3565(25)11335-9","article-title":"Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells","volume":"260","author":"Bolden","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2019.05.003_bib0300","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s40265-013-0105-4","article-title":"Non-dopaminergic treatments for motor control in Parkinson\u2019s disease","volume":"73","author":"Fox","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2019.05.003_bib0305","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/npp.2009.64","article-title":"Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation","volume":"34","author":"Wu","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2019.05.003_bib0310","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/mds.23884","article-title":"The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson\u2019s disease","volume":"26","author":"Seppi","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.drudis.2019.05.003_bib0315","doi-asserted-by":"crossref","first-page":"16023","DOI":"10.1038\/npjparkd.2016.23","article-title":"Non-oral dopaminergic therapies for Parkinson\u2019s disease: current treatments and the future","volume":"2","author":"Chaudhuri","year":"2016","journal-title":"NPJ Parkinson Dis."},{"key":"10.1016\/j.drudis.2019.05.003_bib0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5607\/en.2010.19.1.1","article-title":"Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson\u2019s and Alzheimer\u2019s diseases as disease modifying agents","volume":"19","author":"Youdim","year":"2010","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.drudis.2019.05.003_bib0325","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1517\/13543784.15.8.873","article-title":"Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases","volume":"15","author":"Van der Schyf","year":"2006","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.drudis.2019.05.003_bib0330","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","article-title":"Multi-target therapeutics: when the whole is greater than the sum of the parts","volume":"12","author":"Zimmermann","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2019.05.003_bib0335","first-page":"S71","article-title":"Benefit\/risk of combination therapies","volume":"22","author":"Zerkak","year":"2004","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.drudis.2019.05.003_bib0340","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1586\/ecp.11.13","article-title":"The use of multi-target drugs in the treatment of neurodenegerative diseases","volume":"4","author":"Van der Schyf","year":"2011","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2019.05.003_bib0345","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1359-6446(04)03163-0","article-title":"From magic bullets to designed multiple ligands","volume":"9","author":"Morphy","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2019.05.003_bib0350","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed multiple ligands. An emerging drug discovery paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.05.003_bib0355","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1021\/acs.jcim.7b00316","article-title":"Predicted biological activity of purchasable chemical space","volume":"58","author":"Irwin","year":"2018","journal-title":"J. Chem. Inf. Model"},{"key":"10.1016\/j.drudis.2019.05.003_bib0360","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature08506","article-title":"Predicting new molecular\u2009\u2009targets for known drugs","volume":"462","author":"Keiser","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2019.05.003_bib0365","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/sj.bjp.0707307","article-title":"Chemogenomic approaches to rational drug design","volume":"152","author":"Rognan","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2019.05.003_bib0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-0173(98)00046-0","article-title":"An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration","volume":"29","author":"Cassarino","year":"1999","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.drudis.2019.05.003_bib0375","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.pneurobio.2011.04.010","article-title":"The emergence of designed multiple ligands for neurodegenerative disorders","volume":"94","author":"Geldenbuys","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.drudis.2019.05.003_bib0380","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(14)70117-6","article-title":"The role of iron in brain ageing and neurodegenerative disorders","volume":"13","author":"Ward","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.drudis.2019.05.003_bib0385","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/S1353-8020(13)70032-4","article-title":"Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson\u2019s disease","volume":"20","author":"Youdim","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.drudis.2019.05.003_bib0390","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1471-4159.2005.03340.x","article-title":"Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition","volume":"95","author":"Zheng","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.drudis.2019.05.003_bib0395","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/S1353-8020(11)70047-5","article-title":"M30, a brain permeable multi target neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonisms animal model","volume":"18","author":"Youdim","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.drudis.2019.05.003_bib0400","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.neurobiolaging.2014.10.026","article-title":"Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase A\/monoamine oxidase B inhibitor in animal model of Parkinson\u2019s disease and aging","volume":"36","author":"Bar-Am","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.drudis.2019.05.003_bib0405","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.ejmech.2017.10.050","article-title":"Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-parkinson agents","volume":"143","author":"Carradori","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.05.003_bib0410","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2174\/1573406413666170525125231","article-title":"Quinolinic carboxylic acid derivative sas potential multi-target compounds for neurodegeneration: monamine oxidase and cholinesterase inhibition","volume":"14","author":"Khan","year":"2018","journal-title":"Med. Chem."},{"key":"10.1016\/j.drudis.2019.05.003_bib0415","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3390\/molecules23020250","article-title":"Coumarin: a natural, privileged and versatile scaffold for bioactive compounds","volume":"23","author":"Stefanachi","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2019.05.003_bib0420","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s12031-017-0891-3","article-title":"Neuroprotective effects and mechanism of action of multifunctional agents targeting free radicals, monoamine oxidase B and cholinesterase in Parkinson\u2019s disease model","volume":"61","author":"Liu","year":"2017","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.drudis.2019.05.003_bib0425","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ejmech.2018.02.015","article-title":"Novel indanone derivatives as MAO B\/H3R dual targeting ligands for treatment of Parkinson\u2019s disease","volume":"148","author":"Affini","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.05.003_bib0430","doi-asserted-by":"crossref","first-page":"12765","DOI":"10.1002\/anie.201706072","article-title":"Multitarget-directed ligands combining cholinesterase and monoamine oxidase inhibition with histamine H3R antagonism for neurodegenerative diseases","volume":"56","author":"Bautista-Aguilera","year":"2017","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.drudis.2019.05.003_bib0435","doi-asserted-by":"crossref","first-page":"6937","DOI":"10.1021\/acs.jmedchem.8b00848","article-title":"Contilisant, a tetratarget small molecule for Alzheimer\u2019s disease therapy combining cholinesterase, monoamine oxidase inhibition, and H3R antagonism with S1R agonism profile","volume":"61","author":"Bautista-Aguilera","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.05.003_bib0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.110.003285","article-title":"International union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors \u2014 an update","volume":"63","author":"Fredholm","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.drudis.2019.05.003_bib0445","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.2174\/138161208784480072","article-title":"Adenosine A2A receptor antagonists and Parkinson\u2019s disease: state of the art and future directions","volume":"14","author":"Simola","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.drudis.2019.05.003_bib0450","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1016\/j.bmc.2006.01.011","article-title":"Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC)","volume":"14","author":"Vlok","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.drudis.2019.05.003_bib0455","doi-asserted-by":"crossref","first-page":"8676","DOI":"10.1016\/j.bmc.2008.07.088","article-title":"Dual inhibition of monoamine oxidase B and antagonism of the adenosine A2A receptor by (E,E\u2032)-8-(4-phenylbutadien.1.yl)caffeine analogues","volume":"16","author":"Pretorius","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.drudis.2019.05.003_bib0460","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.nurt.2008.10.035","article-title":"Dual-target-directed drugs that block monoamine oxidase B and adenosine A2A receptors for Parkinson\u2019s disease","volume":"6","author":"Petzer","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.drudis.2019.05.003_bib0465","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.1016\/j.bmc.2016.09.003","article-title":"8-Substituted 1,3-dimethyltetrahydropyrazino[2,1-f]purinediones: water soluble adenosine receptor antagonists and monoamine oxidase B inhibitors","volume":"24","author":"Brunschweiger","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.drudis.2019.05.003_bib0470","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1021\/jm400336x","article-title":"Dual targeting of adenosine A2A receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones","volume":"56","author":"Sto\u03b2el","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.05.003_bib0475","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bioorg.2015.02.005","article-title":"The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues","volume":"59","author":"Van der Walt","year":"2015","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.drudis.2019.05.003_bib0480","doi-asserted-by":"crossref","first-page":"e0188212","DOI":"10.1371\/journal.pone.0188212","article-title":"Discovery of indolylpiperazinylpyrimidines with dual target profiles at adenosine A2A and dopamine D2 receptors for Parkinson\u2019s disease treatment","volume":"13","author":"Shao","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2019.05.003_bib0485","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1021\/mp200489d","article-title":"A novel conjugated agent between dopamine and an A2A adenosine receptor antagonist as a potential anti-Parkinson multitarget approach","volume":"9","author":"Dalpiaz","year":"2012","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.drudis.2019.05.003_bib0490","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1021\/jm060947x","article-title":"Novel ergopeptides as dual ligands for adenosine and dopamine receptors","volume":"5","author":"Vendrell","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.05.003_bib0495","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1021\/acschemneuro.6b00356","article-title":"A novel iron (II) preferring dopamine agonist chelator as potential symptomatic and neuroprotective therapeutic agent for Parkinson\u2019s disease","volume":"8","author":"Das","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.drudis.2019.05.003_bib0500","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.neuropharm.2017.05.019","article-title":"A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses \u03b1-Syn- and MPTP-induced toxicities in vivo","volume":"123","author":"Das","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2019.05.003_bib0505","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13321-017-0249-4","article-title":"Computer-aided design of multi-target ligands at A1R, A2AR and PDE10A, key proteins in neurodegenerative diseases","volume":"9","author":"Kalash","year":"2017","journal-title":"J. Cheminform."},{"key":"10.1016\/j.drudis.2019.05.003_bib0510","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/j.bmc.2016.04.028","article-title":"Structure-guided development of dual b2 adrenergic\/dopamine D2 receptor agonists","volume":"24","author":"Weichert","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.drudis.2019.05.003_bib0515","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cmdc.201800778","article-title":"Triazolotriazine-based dual GSK-3\u03b2\/CK-1\u03b4 ligand as a potential neuroprotective agent presenting two different mechanisms of enzymatic inhibition","volume":"14","author":"Redenti","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drudis.2019.05.003_bib0520","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/1871524918666180426125714","article-title":"Nitrocatechol derivatives of chalcone as inhibitors of monoamine oxidase and catechol-O-methyltransferase","volume":"18","author":"Engelbrecht","year":"2018","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"10.1016\/j.drudis.2019.05.003_bib0525","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s00702-018-1913-1","article-title":"Tetracycline repurposing in neurodegeneration: focus on Parkinson\u2019s disease","volume":"125","author":"Bortolanza","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.drudis.2019.05.003_bib0530","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/14786419.2017.1350669","article-title":"Preliminary studies of berberine and its semisynthetic derivatives as a promising class of multitarget anti-parkinson agents","volume":"32","author":"Ribaudo","year":"2018","journal-title":"Nat. Prod. Res."},{"key":"10.1016\/j.drudis.2019.05.003_bib0535","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.7150\/thno.28295","article-title":"\u201cCell-addictive\u201d dual-target traceable nanodrug for Parkinson\u2019s disease treatment via flotillins pathway","volume":"8","author":"Li","year":"2018","journal-title":"Theranostics"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618300369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618300369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:42:32Z","timestamp":1761223352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644618300369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":108,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1359644618300369"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2019.05.003","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The current status of pharmacotherapy for the treatment of Parkinson\u2019s disease: transition from single-target to multitarget therapy","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2019.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}